Revolution Medicines Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 22.4× Vir Biotechnology Inc. Common Stock's market cap, and Revolution Medicines Inc. Common Stock is more actively traded (2,941,009 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| RVMD | VIR | |
|---|---|---|
Market Cap | $40.39B | $1.80B |
Volume | 2,941,009 | 1,782,836 |
Sector | Health | Health |
52-Week High | $221.15 | $11.78 |
52-Week Low | $49.56 | $5.12 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $37.09B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →